Peptides DB
Research-centric peptide and protocol reference hub
Study 85 of 88HGH (Somatropin) literatureAnalytical chemistry · Observational · Preclinical

Deciphering the In Vivo Fate of PEGylated rhGH via a Molecular Ruler-Based MS Strategy.

The study found that PEG-rhGH has a plasma half-life of 26.83 hours, with low recovery rates indicating delayed elimination, particularly in the liver.

Read at Analytical chemistryAdd to compare

Where it sits

this study against the rest of the hgh (somatropin) corpus
4
Preclinical
59
Observational · this one
1
Open-label
15
Randomised
9
Reviews

Summary and findings

The study measured the in vivo fate of PEGylated recombinant human growth hormone (PEG-rhGH) in rats using a mass spectrometry strategy. The plasma half-life of intact PEG-rhGH was reported as 26.83 hours. Tissue accumulation and metabolite profiling were also assessed, revealing low recovery rates of the intact compound.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
plasma half-life t1/2 = 26.83 hPreclinical

Abstract

The authors’ words, as Analytical chemistry supplied them

A growing number of long-acting protein therapeutics rely on high-molecular-weight (HMW) polyethylene glycol (PEG) conjugation to extend circulation time, yet the in vivo fate of PEG-derived species remains a critical blind spot for drug safety and regulatory evaluation. A key analytical challenge is that intact conjugates and PEG-derived species cannot be resolved by intact-protein or total-PEG measurements alone. Here we report a molecular ruler-based mass spectrometry strategy that integrates MSALL acquisition, PEG standard calibration anchors spanning broad molecular-weight ranges, and a self-built high-resolution mass spectral (HRMS) library to convert broad, overlapping PEG signal envelopes into temporally traceable, molecular-weight-referenced analytical targets. Applied to 40 kDa PEG-modified recombinant human growth hormone (PEG-rhGH) in rats, the workflow quantitatively traced the intact conjugate (plasma half-life t1/2 = 26.83 h) and concurrently resolved tissue-associated PEG 40 kDa and a PEG-related metabolite series. Intact PEG-rhGH remained below the validated tissue LLOQ, whereas PEG-derived components accumulated preferentially in the liver (peak at 48 h), with total urinary and fecal recovery of the quantitatively monitored intact PEG-rhGH and PEG 40 kDa below 10% by 144 hindicating profoundly delayed elimination. HRMS interrogation revealed low-molecular-weight PEG oligomers (PEG7-PEG21) together with carboxylic-acid- and aldehyde-terminated species in liver, consistent with in vivo chain shortening and end-group transformation. By linking intact-conjugate exposure, tissue accumulation, metabolite profiling, and excretion within a single transferable framework, this strategy provides a measurement-science tool for the systematic evaluation of HMW PEGylated protein therapeutics and other pharmaceutical polymer systems.

Background

The paper addresses the in vivo behavior of PEGylated protein therapeutics, which are increasingly used to prolong circulation time. Prior research has highlighted the importance of understanding the fate of PEG-derived species for drug safety and regulatory purposes. This study contributes to the field by presenting a novel mass spectrometry strategy to analyze these compounds.

Methods

The study utilized a molecular ruler-based mass spectrometry strategy to analyze 40 kDa PEG-modified recombinant human growth hormone in rats. The primary outcome measure was the plasma half-life of intact PEG-rhGH, while secondary measures included tissue accumulation and metabolite profiling. Specifics on n and dosing were not reported in abstract.

Results

The primary endpoint revealed a plasma half-life t1/2 of 26.83 hours for intact PEG-rhGH. It was noted that total urinary and fecal recovery of the monitored compounds was below 10% by 144 hours. Additionally, PEG-derived components showed a peak accumulation in the liver at 48 hours.

Interpretation

The findings suggest that while the intact PEG-rhGH has a prolonged half-life, the accumulation of PEG-derived metabolites in the liver raises questions about potential long-term effects. The study's effect sizes, while statistically significant, may not translate to clinically meaningful outcomes without further human data. Limitations include the use of a rodent model and the specific analytical approach, which may not be applicable to all PEGylated therapeutics.

Key findings

  • plasma half-life t1/2 = 26.83 h
  • total urinary and fecal recovery of intact PEG-rhGH and PEG 40 kDa below 10% by 144 h
  • PEG-derived components accumulated preferentially in the liver (peak at 48 h)

Limitations

  • conducted in rats, not humans
  • specific analytical method may not be universally applicable
  • no details on sample size or dosing reported

Elsewhere in the HGH (Somatropin) corpus

BDose optimization and safety of long-acting pegylated growth hormone in pubertal idiopathic short stature: A retrospective real-world group study.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · n=118 · ΔHtSDS: 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001 for high-dose vs. low-dose groups.HumanAOnce-weekly somatrogon versus daily somatropin in pediatric growth hormone deficiency: A systematic review and meta-analysis.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · Not reported in abstract.reviewDAn assessment of the global usability of quality-of-life questionnaires in children receiving recombinant growth hormone therapy.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · 24 (65%) had a reported completion time less than 15 min.reviewBLong-acting growth hormone therapy in Chinese children with idiopathic short stature: efficacy evaluation and influencing factors.Journal of pediatric endocrinology & metabolism : JPEM · 2026 · n=180 · -1.47 ± 0.31 HtSDS vs -1.63 ± 0.48 in control, p<0.001 after 12 monthsHumanDGH-IGF-1 axis and rhGH outcomes in children with GHD, ISS and SGA: a systematic review and meta-analysis.Journal of pediatric endocrinology & metabolism : JPEM · 2026 · Complete GHD showed greater first-year height velocity (HV) than ISS (MD +0.80 cm/year; 95% CI 0.52-1.08).reviewBInfluence of long-acting growth hormone analogs on other hypothalamic-pituitary axes: a real-world study.Journal of endocrinological investigation · 2026 · IGF-I SDS increased significantly in both groups (p<0.001).Human